Ye J, et al. – A research work was carried out to reveal if JCAD promoted progression of non–alcoholic steatohepatitis (NASH) to liver cancer by inhibiting LATS2 kinase activity. A new role for JCAD was emphasised. Also, its critical interplay in the Hippo signaling cascade during the transition of NASH to hepatocellular carcinoma (HCC), with potential implications for therapeutic development in this setting had been elucidated.